The authors of "mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Im…" (https://t.co/ItZw4zUjV1) included RRIDs in their paper! Thank you for making your #methodsmatter. #accelerateopenscience
$lptx mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment (good primer as data nears) https://t.co/AN0ThcBhXv
RT @marketfrankford: This study shows potential for $LPTX DKN-01 in breast cancer and melanoma. $LPTX https://t.co/u8U6jNt1H6
RT @marketfrankford: This study shows potential for $LPTX DKN-01 in breast cancer and melanoma. $LPTX https://t.co/u8U6jNt1H6
RT @marketfrankford: This study shows potential for $LPTX DKN-01 in breast cancer and melanoma. $LPTX https://t.co/u8U6jNt1H6
RT @marketfrankford: This study shows potential for $LPTX DKN-01 in breast cancer and melanoma. $LPTX https://t.co/u8U6jNt1H6
$LPTX Very good article! #Cancers #BreakingNews #biotech
This study shows potential for $LPTX DKN-01 in breast cancer and melanoma. $LPTX https://t.co/u8U6jNt1H6
Outstanding!
RT @nolastevedore: @srqstockpicker $LPTX Published April 2021 in Molecular Cancer Research, although released online earlier "mDKN-01, a…
@srqstockpicker $LPTX Published April 2021 in Molecular Cancer Research, although released online earlier "mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment" DKK1 has potential in many cancers: GEJ, breast, l
@Pharmdca $LPTX Published April 2021 in Molecular Cancer Research in print, although released online earlier "mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment" Potential in many cancers: GEJ, breast, lung, p
Anti-DKK1 #MonoclonalAntibody mDKN-01 reverses a DKK1 mediated innate immune suppression in the #TumorMicroenvironment and has additive efficacy with a PD-1 inhibitor. @LeapTherapeutic https://t.co/MzQJfgQZuf https://t.co/1PZPDzj7kQ
Anti-DKK1 #MonoclonalAntibody mDKN-01 reverses a DKK1 mediated innate immune suppression in the #TumorMicroenvironment and has additive efficacy with a PD-1 inhibitor. @LeapTherapeutic https://t.co/zNBP0WMwUr https://t.co/SEXxN0qlH1
Check out this new @MCR_AACR publication in which we produced the mDKN-01 antibody which was found to enhance innate immune response in the tumor microenvironment. https://t.co/F3UlSkRVmr
mDKN-01, a Novel Anti-DKK1 Monoclonal Antibody, Enhances Innate Immune Responses in the Tumor Microenvironment. by Haas MS, Kagey MH, Heath H, Schuerpf F, Newman W, Rottman JB https://t.co/6NIoNs9ef4
Anti-DKK1 #MonoclonalAntibody mDKN-01 reverses a DKK1 mediated innate immune suppression in the #TumorMicroenvironment and has additive efficacy with a PD-1 inhibitor. @LeapTherapeutic https://t.co/icA0auACbJ https://t.co/uEzu01fP6u
RT @LeapTherapeutic: “The additive effect of DKK1 and PD-1 co-blockade further supports Leap’s Phase 2 DisTinGuish study, investigating DKN…
RT @Kevin_W81: $LPTX
RT @LeapTherapeutic: “The additive effect of DKK1 and PD-1 co-blockade further supports Leap’s Phase 2 DisTinGuish study, investigating DKN…
RT @Kevin_W81: $LPTX
$LPTX
$LPTX
RT @LeapTherapeutic: “The additive effect of DKK1 and PD-1 co-blockade further supports Leap’s Phase 2 DisTinGuish study, investigating DKN…
“The additive effect of DKK1 and PD-1 co-blockade further supports Leap’s Phase 2 DisTinGuish study, investigating DKN-01 and Tislelizumab with and without chemotherapy” - Jay Baum, Vice President and Head of Translational Medicine at Leap Therapeutics. ht